Cui J - Search Results

1

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.

Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Wu F, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Jin F, Gao H, An G, Ding C, Jiang X, Xiong J, Zhou X, Hu S, Lu P, Liu A, Guo S, Huang J, Zhu C, Zhao J, Gao B, Chen Y, Hu C, Zhang J, Zhang H, Zhao H, Wang Z, Ma X, Shi W. Zhou C, et al. Among authors: cui j. J Immunother Cancer. 2024 Nov 27;12(11):e009240. doi: 10.1136/jitc-2024-009240. J Immunother Cancer. 2024. PMID: 39608979 Free PMC article. Clinical Trial.

2

Plasma 25-hydroxyvitamin D deficiency is associated with the risk of non-small cell lung cancer in a Chinese population.

Wang X, Cui J, Gu J, He H, Li B, Li W. Wang X, et al. Among authors: cui j. Cancer Biomark. 2015;15(5):663-8. doi: 10.3233/CBM-150506. Cancer Biomark. 2015. PMID: 26406955

3

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.

Wang Y, Wang C, Xiao H, Niu C, Wu H, Jin H, Yao C, He H, Tian H, Han F, Li D, Han W, Xu J, Chen J, Cui J, Li W. Wang Y, et al. Among authors: cui j. Cancer Med. 2017 Jan;6(1):45-53. doi: 10.1002/cam4.942. Epub 2016 Oct 27. Cancer Med. 2017. PMID: 27790867 Free PMC article.

4

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

Wu YL, Wang CL, Sun Y, Liao ML, Guan ZZ, Yang ZM, Zhou QH, Lu S, Cheng Y, Liu XQ, Zhang XC, Zhou C, Wang J, Zhou Q, Song Y, Han BH, Ma ZY, Yang F, Wang Q, Chuai SK, Shao Y, He W, Zhu G, Xiong L, Wang JJ, Chen KN, Zhang L, Mao WM, Ma SL, Feng JF, Yang XN, Xu L, Chen G, Zhao J, Song QB, Shen-Tu Y, Qiao GB, Yu D, Yu SY, Hu Y, Chen M, Chen GY, Fan Y, Zhang HL, Liang J, Zhu GY, Cui JW, Yang JJ, Zhao Q, Zhao MF, Lu Y, Chang JH, Li JL, Yang Y, Hu J, Gu CD, Zhang YC, Zhong WZ. Wu YL, et al. Among authors: cui jw. ESMO Open. 2017 Apr 4;2(Suppl 1):e000174. doi: 10.1136/esmoopen-2017-000174. eCollection 2017. ESMO Open. 2017. PMID: 28848676 Free PMC article. Review.

5

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Dong J, Wang X, Yu Y, Yan X, Cui JW. Dong J, et al. Among authors: cui jw. Chin Med J (Engl). 2018 Aug 20;131(16):1904-1908. doi: 10.4103/0366-6999.238141. Chin Med J (Engl). 2018. PMID: 30082520 Free PMC article.

6

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation  Treated by Immune Checkpoint Inhibitors].

Bai R, Chen N, Cui J. Bai R, et al. Among authors: cui j. Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):641-648. doi: 10.3779/j.issn.1009-3419.2018.08.11. Zhongguo Fei Ai Za Zhi. 2018. PMID: 30172273 Free PMC article. Review. Chinese.

7

Survival prediction with score model based on clinical characteristics in advanced HCC patients receiving oxaliplatin-containing regimens.

Qian L, Dong YB, Zhao LL, Zhao HJ, Cui JW, Wang NY. Qian L, et al. Among authors: cui jw. Neoplasma. 2019 Mar 5;66(2):301-307. doi: 10.4149/neo_2018_180706N448. Epub 2018 Nov 23. Neoplasma. 2019. PMID: 30509107

8

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).

Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Song Y, et al. Among authors: cui jw. Am J Clin Oncol. 2019 May;42(5):432-439. doi: 10.1097/COC.0000000000000538. Am J Clin Oncol. 2019. PMID: 30950859 Free PMC article. Clinical Trial.

9

First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.

Li LY, Wang H, Chen X, Li WQ, Cui JW. Li LY, et al. Chin Med J (Engl). 2019 Dec 5;132(23):2790-2794. doi: 10.1097/CM9.0000000000000536. Chin Med J (Engl). 2019. PMID: 31856049 Free PMC article.

10

Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.

Li W, Bai R, Qian L, Chen N, Zhao Y, Han F, Bai L, Li J, Yu Y, Cui J. Li W, et al. Among authors: cui j. Asia Pac J Clin Oncol. 2021 Apr;17(2):e40-e47. doi: 10.1111/ajco.13291. Epub 2020 Jan 19. Asia Pac J Clin Oncol. 2021. PMID: 31957251

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,691 results

Search Page

Filters